<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935699</url>
  </required_header>
  <id_info>
    <org_study_id>ETTAU-03</org_study_id>
    <nct_id>NCT02935699</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria</brief_title>
  <official_title>A Phase III, Multi-center, Double Blind, Randomized, Active Controlled Clinical Trial to Evaluate the Non-Inferiority Comparing Cetirizine Injection 10 mg to Diphenhydramine Injection, 50 mg, for the Treatment of Acute Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JDP Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JDP Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III
      clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50
      mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multi-center, parallel group, randomized, double-blind, active controlled, Phase
      III clinical trial of cetirizine injection 10 mg/mL versus diphenhydramine injection 50 mg/mL
      (Benadryl or generic equivalent) in approximately 256 subjects who either presented to
      Emergency Departments, hospitals, allergy clinics or Urgent Care Centers with acute
      urticaria, or developed acute urticaria following allergen challenge at an Allergy Clinic.

      Patients signed an informed consent and were evaluated for eligibility for inclusion to
      treat. Eligible subjects were assessed for baseline characteristics, medical and surgical
      histories, concomitant medications and given a brief physical exam.

      Subjects were then randomized, in a 1:1 ratio, to blindly receive either cetirizine 10 mg/mL
      injection or diphenhydramine 50 mg/mL injection.

      Efficacy assessments included patient-rated severity of pruritus, physician assessments of
      extent of urticaria/erythema, and sedation score. Subjects remained in the treatment center
      for at least after the 1 hr assessment, after which they may have been discharged at the
      physician's discretion.

      Safety was monitored through the reporting of adverse events for up to 28 days following
      treatments and by monitoring vital signs at planned intervals from admission into the
      treating facility until readiness for discharge. After 24 and 48 hrs after discharge,
      subjects were contacted by phone for follow-up questions regarding recurrence of symptoms,
      new symptoms, additional medication taken, side effects from medication taken after
      discharge, relapse requiring a return to treatment center, and return to normal activities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Patient Rated Pruritus Score</measure>
    <time_frame>2 hr</time_frame>
    <description>Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline)
Patient Pruritus Severity Score Ask the patient &quot;How severely are your hives itching at the moment?&quot; 0 = none
= mild (minimal awareness, easily tolerated)
= moderate (definite awareness, quite bothersome)
= severe (difficult to tolerate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Needed to Return to Treatment Center</measure>
    <time_frame>up to 24 hrs</time_frame>
    <description>Number of patients who needed to return to treatment center approximately 24 hours after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Time spent (hours) at the treatment center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Sedation Scores</measure>
    <time_frame>2 hours</time_frame>
    <description>Patient Sedation Score at 2 hours
Ask the patient &quot;How drowsy do you feel at the moment?&quot; 0 = None (Not drowsy at all)
= Mild (Slightly drowsy)
= Moderate (Quite drowsy)
= Severe (Extremely drowsy)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Acute Urticaria</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JDP-205 Injection, 10 mg/mL, 1 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diphenhydramine Injection, 50 mg/mL, 1 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Drug (JDP-205)</intervention_name>
    <description>Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes</description>
    <arm_group_label>Test Drug</arm_group_label>
    <other_name>QUZYTTIR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Control (Diphenhydramine)</intervention_name>
    <description>Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients with a diagnosis of acute urticaria who need treatment with
             antihistamine to alleviate their symptoms;

          2. 18 years of age or older;

          3. Be willing and able to give informed consent;

          4. Patients with a Patient rated Pruritus Severity Score â‰¥ 1

        Exclusion Criteria:

          1. Receipt of an investigational drug or device, within the past 30 days;

          2. Patients in whom an antihistamine may be contraindicated (e.g. narrow angle glaucoma,
             symptomatic prostatic hypertrophy);

          3. Patients who, in the opinion of the investigator, may not tolerate an IV injection of
             diphenhydramine 50 mg, or cetirizine 10 mg;

          4. Receipt of any antihistamine (H1 antagonist) within the past 2 hours regardless of the
             route of administration, e.g. diphenhydramine, cetirizine, loratadine, fexofenadine,
             levocetirizine, desloratadine;

          5. Receipt of an H2 antagonist within the past 2 hours;

          6. Receipt of doxepin within the past 2 hours; doxepin is an antidepressant, but it also
             has antihistamine properties;

          7. Receipt of steroids by the oral, IV, IM, or inhalational routes route within the past
             4 hours to manage an acute allergic reaction;

          8. Receipt of epinephrine (EpiPen or any other brand) within the past 20 minutes;

          9. Anaphylaxis prior to the acute anaphylactic symptoms having been treated.

         10. Has known allergy to hydroxyzine, cetirizine or levocetirizine, or diphenhydramine;

         11. Pregnancy or breastfeeding;

         12. Patients who have an acute allergic reaction to medication they are taking (e.g.
             antibiotics, NSAIDs, etc.) and who cannot stop the medication;

         13. Patients who, based on their medical history or in the opinion of the investigator,
             have chronic urticaria, hereditary angioedema, urticaria refractory to antihistamines,
             or dermatological disease that interferes with evaluation of a therapeutic response;

         14. Any condition that in the view of the investigator makes the subject unsuitable for
             enrollment in this study;

         15. History of HIV or other known immunodeficiency;

         16. Major medical or psychiatric illness, other than acute urticaria, at the time of
             presentation;

         17. Inability to provide informed consent.

         18. Patients on concomitant p-glycoprotein inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JIE DU, PH.D.</last_name>
    <role>Study Chair</role>
    <affiliation>JDP Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Doc Urgent Care center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://jdptherapeutics.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <results_first_submitted>October 18, 2019</results_first_submitted>
  <results_first_submitted_qc>November 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <last_update_submitted>November 9, 2019</last_update_submitted>
  <last_update_submitted_qc>November 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02935699/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02935699/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Drug</title>
          <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Drug</title>
          <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="16.28"/>
                    <measurement group_id="B2" value="39.2" spread="15.96"/>
                    <measurement group_id="B3" value="39.1" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Patient Rated Pruritus Score</title>
        <description>Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline)
Patient Pruritus Severity Score Ask the patient &quot;How severely are your hives itching at the moment?&quot; 0 = none
= mild (minimal awareness, easily tolerated)
= moderate (definite awareness, quite bothersome)
= severe (difficult to tolerate)</description>
        <time_frame>2 hr</time_frame>
        <population>Intent To Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Drug</title>
            <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Patient Rated Pruritus Score</title>
          <description>Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline)
Patient Pruritus Severity Score Ask the patient &quot;How severely are your hives itching at the moment?&quot; 0 = none
= mild (minimal awareness, easily tolerated)
= moderate (definite awareness, quite bothersome)
= severe (difficult to tolerate)</description>
          <population>Intent To Treat population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="0.944"/>
                    <measurement group_id="O2" value="-1.50" spread="0.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Needed to Return to Treatment Center</title>
        <description>Number of patients who needed to return to treatment center approximately 24 hours after discharge</description>
        <time_frame>up to 24 hrs</time_frame>
        <population>Intent To Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Drug</title>
            <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Needed to Return to Treatment Center</title>
          <description>Number of patients who needed to return to treatment center approximately 24 hours after discharge</description>
          <population>Intent To Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge</title>
        <description>Time spent (hours) at the treatment center</description>
        <time_frame>up to 24 hours</time_frame>
        <population>Intent To Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Drug</title>
            <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge</title>
          <description>Time spent (hours) at the treatment center</description>
          <population>Intent To Treat Population</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.868"/>
                    <measurement group_id="O2" value="2.07" spread="1.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Sedation Scores</title>
        <description>Patient Sedation Score at 2 hours
Ask the patient &quot;How drowsy do you feel at the moment?&quot; 0 = None (Not drowsy at all)
= Mild (Slightly drowsy)
= Moderate (Quite drowsy)
= Severe (Extremely drowsy)</description>
        <time_frame>2 hours</time_frame>
        <population>Intent To Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Drug</title>
            <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Sedation Scores</title>
          <description>Patient Sedation Score at 2 hours
Ask the patient &quot;How drowsy do you feel at the moment?&quot; 0 = None (Not drowsy at all)
= Mild (Slightly drowsy)
= Moderate (Quite drowsy)
= Severe (Extremely drowsy)</description>
          <population>Intent To Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.721"/>
                    <measurement group_id="O2" value="0.88" spread="0.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Drug</title>
          <description>JDP-205 Injection, 10 mg/mL, 1 mL
Test Drug (JDP-205): JDP-205 Injection, 10 mg/mL, 1 mL</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Diphenhydramine Injection, 50 mg/mL, 1 mL
Active Control (Diphenhydramine): Diphenhydramine Injection, 50 mg/mL</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>TerSera Therapeutics</organization>
      <phone>844-334-4035</phone>
      <email>tersera@medinfodept.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

